In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy.

Journal of Cellular Physiology
Yingyu ChenQizhen Shi

Abstract

Our previous studies have demonstrated that platelet-targeted factor IX (FIX) gene therapy can introduce sustained platelet-FIX expression in hemophilia B (FIXnull ) mice. In this study, we aimed to enhance platelet-FIX expression in FIXnull mice with O6 -methylguanine-DNA-methyltransferase (MGMT)-mediated in vivo drug selection of transduced cells under nonmyeloablative preconditioning. We constructed a novel lentiviral vector (2bF9/MGMT lentivirus vector), which harbors dual genes, the FIX gene driven by the αIIb promoter (2bF9) and the MGMT P140K gene under the murine stem cell virus promoter. Platelet-FIX expression in FIXnull mice was introduced by 2bF9/MGMT-mediated hematopoietic stem cell transduction and transplantation. The 2bF9/MGMT-transduced cells were effectively enriched after drug selection by O6 -benzylguanine/1,3-bis-2-chloroethyl-1-nitrosourea. There were a 2.9-fold higher FIX antigen and a 3.7-fold higher FIX activity in platelets, respectively, posttreatment compared with pretreatment. When a 6-hr tail bleeding test was used to grade the bleeding phenotype, the clotting time in treated animals was 2.6 ± 0.5 hr. In contrast, none of the FIXnull control mice were able to clot within 6 hr. Notably, none of the ...Continue Reading

References

May 13, 1995·Lancet·T N ElstonS A Schey
Mar 29, 2002·Bone Marrow Transplantation·A A ToorN S Key
Nov 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas F GajewskiEverett E Vokes
Feb 3, 2007·Journal of Thrombosis and Haemostasis : JTH·Q ShiR R Montgomery
Dec 14, 2011·The New England Journal of Medicine·Amit C NathwaniAndrew M Davidoff
May 29, 2012·Journal of Thrombosis and Haemostasis : JTH·E L KuetherQ Shi
Jul 11, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·A SrivastavaUNKNOWN Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia
Aug 9, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Rustom FalahatiKarin Ml Gaensler
Sep 18, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yingyu ChenQizhen Shi
Jan 21, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Daniela CesanaEugenio Montini
Nov 20, 2014·The New England Journal of Medicine·Amit C NathwaniAndrew M Davidoff
Mar 12, 2016·Blood·Margaret V Ragni
Aug 25, 2017·Human Gene Therapy·Amit C NathwaniEdward G D Tuddenham
Oct 12, 2017·Blood·Valder R ArrudaBenjamin J Samelson-Jones
Nov 22, 2017·Human Gene Therapy Methods·S Louise PayMichael E Boulton
Dec 7, 2017·The New England Journal of Medicine·Lindsey A GeorgeKatherine A High
Jan 4, 2018·Blood Advances·Lindsey A George
Mar 3, 2018·Blood·Michael Makris
Mar 10, 2018·Molecular Therapy. Methods & Clinical Development·Qizhen Shi
Nov 14, 2018·The Journal of Clinical Investigation·Hongjie WangAndré Lieber
Dec 14, 2018·Molecular Therapy. Methods & Clinical Development·Jenny A GreigJames M Wilson
Dec 19, 2018·Blood·George Q PerrinDavid M Markusic
Dec 19, 2018·Blood·Angela C Weyand, Steven W Pipe
Jan 4, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Glenn F PierceUNKNOWN Members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee
Feb 17, 2019·Journal of Controlled Release : Official Journal of the Controlled Release Society·Calvin J StephensDavid T Curiel
Nov 7, 2019·Journal of Cellular Physiology·Navid ShomaliFaroogh Marofi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.